EFTA01092526Set 9
2012-07-161p883w
druggable because they do not possess
them larger than most small molecules but Investors: Hatteras Venture Partners: enzymatic activity until a pair of groups
smaller than biologics (see "Ito Materials ... delivery of larger The company picked up the technol- series B round include Hatteras Venture;
post-assembly agents. ogy at the concept stage in 2009, and Medlmmune Ventures; and Ascent
https://www.justice.gov/epstein/files/DataSet%209/EFTA01092526.pdf